Display options
Cite
Ferro M, de Cobelli O, Musi G, et al. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Front Oncol. 2021;11:651745doi: 10.3389/fonc.2021.651745.
Ferro, M., de Cobelli, O., Musi, G., Lucarelli, G., Terracciano, D., Pacella, D., Muto, T., Porreca, A., Busetto, G. M., Del Giudice, F., Soria, F., Gontero, P., Cantiello, F., Damiano, R., Crocerossa, F., Farhan, A. R. A., Autorino, R., Vartolomei, M. D., Muto, M., Marchioni, M., Mari, A., Scafuri, L., Minervini, A., Longo, N., Chiancone, F., Perdona, S., De Placido, P., Verde, A., Catellani, M., Luzzago, S., Mistretta, F. A., Ditonno, P., Caputo, V. F., Battaglia, M., Zamboni, S., Antonelli, A., Greco, F., Russo, G. I., Hurle, R., Crisan, N., Manfredi, M., Porpiglia, F., Di Lorenzo, G., Crocetto, F., & Buonerba, C. (2021). Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Frontiers in oncology, 11651745. https://doi.org/10.3389/fonc.2021.651745
Ferro, Matteo, et al. "Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis." Frontiers in oncology vol. 11 (2021): 651745. doi: https://doi.org/10.3389/fonc.2021.651745
Ferro M, de Cobelli O, Musi G, Lucarelli G, Terracciano D, Pacella D, Muto T, Porreca A, Busetto GM, Del Giudice F, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Farhan ARA, Autorino R, Vartolomei MD, Muto M, Marchioni M, Mari A, Scafuri L, Minervini A, Longo N, Chiancone F, Perdona S, De Placido P, Verde A, Catellani M, Luzzago S, Mistretta FA, Ditonno P, Caputo VF, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Hurle R, Crisan N, Manfredi M, Porpiglia F, Di Lorenzo G, Crocetto F, Buonerba C. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Front Oncol. 2021 May 11;11:651745. doi: 10.3389/fonc.2021.651745. eCollection 2021. PMID: 34046347; PMCID: PMC8144638.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 May 11;11:651745. doi: 10.3389/fonc.2021.651745. eCollection 2021.

Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis.

Frontiers in oncology

Matteo Ferro, Ottavio de Cobelli, Gennaro Musi, Giuseppe Lucarelli, Daniela Terracciano, Daniela Pacella, Tommaso Muto, Angelo Porreca, Gian Maria Busetto, Francesco Del Giudice, Francesco Soria, Paolo Gontero, Francesco Cantiello, Rocco Damiano, Fabio Crocerossa, Abdal Rahman Abu Farhan, Riccardo Autorino, Mihai Dorin Vartolomei, Matteo Muto, Michele Marchioni, Andrea Mari, Luca Scafuri, Andrea Minervini, Nicola Longo, Francesco Chiancone, Sisto Perdona, Pietro De Placido, Antonio Verde, Michele Catellani, Stefano Luzzago, Francesco Alessandro Mistretta, Pasquale Ditonno, Vincenzo Francesco Caputo, Michele Battaglia, Stefania Zamboni, Alessandro Antonelli, Francesco Greco, Giorgio Ivan Russo, Rodolfo Hurle, Nicolae Crisan, Matteo Manfredi, Francesco Porpiglia, Giuseppe Di Lorenzo, Felice Crocetto, Carlo Buonerba

Affiliations

  1. Division of Urology of European Institute of Oncology (IEO), IRCCS, Milan, Italy.
  2. Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, University of Milan, Milan, Italy.
  3. Department of Emergency and Organ Transplantation, School of Medicine, University of Bari Aldo Moro, Bari, Italy.
  4. Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
  5. Department of Public Health, University of Naples Federico II, Naples, Italy.
  6. Oncological Urology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  7. Department of Urology and Renal Transplantation, University of Foggia Policlinico Riuniti of Foggia, Foggia, Italy.
  8. Department of Urology, Sapienza University of Rome, Rome, Italy.
  9. Division of Urology, Department of Surgical Sciences, AOU Cittá della Salute e della Scienza, Torino School of Medicine, Turin, Italy.
  10. Department of Urology, University of Catanzaro, UNIVERSITÁ "MAGNA GRÆCIA" di Catanzaro, Catanzaro, Italy.
  11. Division of Urology, Virginia Commonwealth University Health System, Richmond, VA, United States.
  12. Department of Urology, Vienna General Hospital, Vienna, Austria.
  13. Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mure?, Tirgu Mures, Romania.
  14. Department of Hematology, Oncology and Radiotherapy Azienda ospedaliera San Giuseppe Moscati, Avellino, Avelino, Italy.
  15. Department of Urology, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy.
  16. Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy.
  17. Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  18. Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy.
  19. Division of Urology, Hospital Antonio Cardarelli, Naples, Italy.
  20. Division of Urology, Istituto Nazionale Tumori Fondazione G. Pascale (IRCCS), Naples, Italy.
  21. Department of Urology, Civil Hospital of Brescia, Brescia, Italy.
  22. Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona - Polo Chirurgico Confortini - Borgo Trento, Verona, Italy.
  23. Department of Urology, Humanitas Gavazzeni, IRRCS, Bergamo, Italy.
  24. Department of Urology, University of Catania, Catania, Italy.
  25. Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy.
  26. Department of Urology, Iuliu Ha?ieganu University of Medicine and Pharmacy, Ciuj Napoca, Romania.
  27. Urology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy.
  28. Department of Urology, Humanitas Research Hospital Milano, Milan, Italy.
  29. Department of Medicine and Health Science, University of Molise, Campobasso, Italy.
  30. Rare Tumor Reference Center, Federico II University Hospital, Naples, Italy.
  31. Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

PMID: 34046347 PMCID: PMC8144638 DOI: 10.3389/fonc.2021.651745

Abstract

BACKGROUND: Three or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also commonly administered in clinical practice. In this multicenter retrospective study, we assessed a large and homogenous cohort of patients with urothelial bladder cancer (UBC) treated with three or four cycles of neoadjuvant cisplatin-gemcitabine followed by radical cystectomy, in order to explore whether three vs. four cycles were associated with different outcomes.

METHODS: Patients with histologically confirmed muscle-invasive UBC included in this retrospective study had to be treated with either 3 (cohort A) or 4 (cohort B) cycles of cisplatin-gemcitabine as neoadjuvant therapy before undergoing radical cystectomy with lymphadenectomy. Outcomes including pathologic downstaging to non-muscle invasive disease, pathologic complete response (defined as absence of disease -ypT0), overall- and cancer-specific- survival as well as time to recurrence were compared between cohorts A vs. B.

RESULTS: A total of 219 patients treated at 14 different high-volume Institutions were included in this retrospective study. Patients who received 3 (cohort A) vs. 4 (cohort B) cycles of neoadjuvant cisplatin-gemcitabine were 160 (73,1%) vs. 59 (26,9%).At univariate analysis, the number of neoadjuvant cycles was not associated with either pathologic complete response, pathologic downstaging, time to recurrence, cancer specific, and overall survival. Of note, patients in cohort B vs. A showed a worse non-cancer specific overall survival at univariate analysis (HR= 2.53; 95 CI= 1.05 - 6.10; p=0.046), although this finding was not confirmed at multivariate analysis.

CONCLUSIONS: Our findings suggest that 3 cycles of cisplatin-gemcitabine may be equally effective, with less long-term toxicity, compared to 4 cycles in the neoadjuvant setting.

Copyright © 2021 Ferro, de Cobelli, Musi, Lucarelli, Terracciano, Pacella, Muto, Porreca, Busetto, Del Giudice, Soria, Gontero, Cantiello, Damiano, Crocerossa, Farhan, Autorino, Vartolomei, Muto, Marchioni, Mari, Scafuri, Minervini, Longo, Chiancone, Perdona, De Placido, Verde, Catellani, Luzzago, Mistretta, Ditonno, Caputo, Battaglia, Zamboni, Antonelli, Greco, Russo, Hurle, Crisan, Manfredi, Porpiglia, Di Lorenzo, Crocetto and Buonerba.

Keywords: bladder cancer; cisplatin-based chemotherapy; neoadjuvant chemotherapy; observational study; radical cystectomy

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. World J Urol. 2020 Jan;38(1):143-150 - PubMed
  2. Future Oncol. 2010 Sep;6(9):1365-8 - PubMed
  3. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354 - PubMed
  4. Oncologist. 2016 Jun;21(6):708-15 - PubMed
  5. Eur Urol. 2021 Jan;79(1):82-104 - PubMed
  6. Eur Urol. 2021 Feb;79(2):214-221 - PubMed
  7. Crit Rev Oncol Hematol. 2015 Dec;96(3):534-41 - PubMed
  8. Minerva Urol Nefrol. 2007 Mar;59(1):67-87 - PubMed
  9. World J Urol. 2019 Jan;37(1):3-13 - PubMed
  10. Nat Med. 2020 Dec;26(12):1839-1844 - PubMed
  11. Minerva Urol Nefrol. 2014 Mar;66(1):1-14 - PubMed
  12. Minerva Urol Nefrol. 2020 Oct;72(5):641-643 - PubMed
  13. Cancer. 2008 Nov 1;113(9):2471-7 - PubMed
  14. Prog Clin Biol Res. 1984;162A:11-25 - PubMed
  15. Oncol Rep. 2012 Feb;27(2):409-15 - PubMed
  16. Clin Cancer Res. 2021 May 1;27(9):2435-2441 - PubMed
  17. Cancer. 2015 Aug 1;121(15):2586-93 - PubMed
  18. Jpn J Clin Oncol. 2018 Oct 1;48(10):934-941 - PubMed
  19. Eur Urol Oncol. 2020 Aug 23;: - PubMed

Publication Types